Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  keyhole limpet hemocyanin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 37 for your search:
Start Over
Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1694, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9
Phase III Multicenter, Randomized, Controlled Study of THERATOPE Vaccine in Women With Metastatic Breast Cancer (Summary Last Modified 05/2001)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BIOMIRA-STn-BR-104, NCI-V98-1489, NCT00003638
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX110-04, NCT01480479
Phase I/II Pilot Study of Anti-Idiotypic MOAB BEC2 Conjugated to KLH plus BCG as Adjuvant in Completely Resected Melanoma (Summary Last Modified 03/95)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-94078, NCI-H94-0538
Dendritic Cell Based Therapy of Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UR0414, NCT00197860
Dendritic Cell Based Therapy of Malignant Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: MM0413, NCT00197912
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ERLANGEN-DERMA-ER-DC-06, CDR0000343699, EU-20317, NCT00074230
Phase II Study of Tumor-Derived Immunoglobulin Idiotype Vaccination and Sargramostim following Cyclophosphamide/Doxorubicin/Etoposide/Prednisone in Low-Grade Follicular Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-96-C-0133, CRB-9309, NCI-T93-0164N, T93-0164, NCT00878488
Phase II Study of Active Immunization of Related Bone Marrow Transplant Donors Against Purified Myeloma Protein from the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Phase: Phase II
Type: Treatment
Status: Completed
Age: under 60
Sponsor: NCI
Protocol IDs: NCI-97-C-0030B, CRB-9407, NCI-T94-0085N, T94-0085
Vaccine Therapy in Treating Patients With Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000064244, NCI-97-C-0033B, NCI-T94-0094N, CRB-9409, T94-0094, NCT00019097
Phase II Study of Allogeneic T-Cell-Depleted BMT, Followed by Transplantation of Allogeneic T Cells from Idiotype-Vaccinated Donors, for Multiple Myeloma (Summary Last Modified 04/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI, NHLBI
Protocol IDs: NHLBI-T96-0017, NCI-T96-0017N, T96-0017
Phase II Study of Vaccination with Tn(c)-KLH Conjugate Plus the Immunological Adjuvant QS21 in Patients with Prostate Cancer (Summary Last Modified 05/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98002, NCI-G98-1440
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: 197-99, P30CA036727, UNMC-197-99, GENITOPE-9902, SUMC-9902, NCT00004197
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: 196-99, P30CA036727, UNMC-196-99, GENITOPE-9901, NCT00004198
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 000133, 00-C-0133, NCI-00-C-0133, NCI-1033, NCT00020215, NCT00005780
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: NCI
Protocol IDs: 000201, 00-C-0201, NCI-00-C-0201, NCI-1029, 1029, NCT00020306, NCT00006184
Phase II Study of Autologous Tumor Cell Vaccine With Adjuvant Sargramostim (GM-CSF) in Patients With Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FAV-ID-01, SKCC-2001, SKCC-BB-IND-8786
Phase II Pilot Adjuvant Study of Vaccination with Sialyl Tn Antigen Covalenty Attached to KLH plus Detox in Patients with High-Risk Resected Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor:
Protocol IDs: MSKCC-91095, NCI-V91-0167
Phase II Pilot Study of Vaccination with Sialyl Tn Antigen Covalently Attached to KLH plus QS21 in High-Risk Resected Colorectal Cancer (Summary Last Modified 07/95)
Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-92100, NCI-V92-0144
Start Over